Regulatory information – adjusted fees for applications to EMA from 1 April 2023
News
Corporate
The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2023.
Every year, the European Commission adopts a regulation adjusting the fees payable to the Agency with reference to the inflation rate in the European Union for the previous year. The 2022 inflation rate was 10.4%.
EMA published full details of the revised fees following the adoption of the Commission Regulation (EU) 2023/699 of 29 March 2023 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2023. The Agency's Management Board decided on the implementation of the regulation at its March 2023 meeting.
Fees charged for pharmacovigilance procedures in accordance with Regulation (EU) 658/2014 are expected to be revised by the same percentage later in 2023.